Australia markets open in 7 hours 38 minutes

Pfizer Inc. (0Q1N.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
50.83+0.25 (+0.49%)
As of 07:12PM BST. Market open.
Full screen
Loading interactive chart…
  • Business Wire

    Pfizer Completes Acquisition of Global Blood Therapeutics

    NEW YORK, October 05, 2022--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space.

  • Business Wire

    Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

    NEW YORK, October 04, 2022--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The study met its primary endpoint with a statistically significant and clinica

  • Business Wire

    Pfizer Completes Acquisition of Biohaven Pharmaceuticals

    NEW YORK, October 03, 2022--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.